In a patient with grade 1 invasive ductal carcinoma, Ki‑67 1%, HER2‑negative and hormone‑receptor‑positive, does chemotherapy provide benefit?

Grade 1 IDC with Ki-67 1%, HER2-Negative, HR-Positive: Chemotherapy Not Recommended

For a patient with grade 1 invasive ductal carcinoma, Ki-67 1%, HER2-negative and hormone-receptor-positive breast cancer, chemotherapy provides no meaningful benefit and should not be administered—endocrine therapy alone is the appropriate treatment.

Rationale Based on Current Evidence

Tumor Biology Indicates Excellent Prognosis

Your patient's tumor demonstrates the most favorable biological characteristics possible:

• Grade 1 histology = lowest proliferative activity and best differentiation
• Ki-67 of 1% = extremely low proliferation (well below any threshold suggesting chemotherapy benefit)
• HR-positive = highly endocrine responsive
• HER2-negative = no indication for anti-HER2 therapy

The 2024 ESMO guidelines explicitly state that low grade combined with low Ki-67 and strong ER/PR expression identifies patients with sufficiently favorable biology who do not benefit from chemotherapy 1. Among postmenopausal women with node-negative disease or 1-3 positive nodes and low-risk biology, adjuvant chemotherapy did not reduce recurrence rates compared with endocrine therapy alone 1.

Ki-67 as a Predictive Marker for Chemotherapy Benefit

The evidence consistently demonstrates that chemotherapy benefit correlates with higher Ki-67 levels:

• Research shows that patients benefiting from chemotherapy typically have Ki-67 ≥19-35% 2, 3
• One study identified Ki-67 ≥32% as the threshold where chemotherapy added to endocrine therapy showed benefit in node-positive, luminal B disease 3
• Another found that Ki-67 ≥35% distinguished patients who might benefit from chemotherapy 4
• The 2011 International Ki67 Working Group noted that high Ki-67 predicted benefit from adding chemotherapy in ER-positive tumors, but this was in the context of much higher proliferation rates 5

Your patient's Ki-67 of 1% is far below any threshold suggesting chemotherapy responsiveness. Tumors with such low proliferation are inherently chemotherapy-resistant because cytotoxic agents primarily target rapidly dividing cells.

Clinical Practice Guidelines Support Endocrine Therapy Alone

The 2025 St. Gallen consensus emphasizes that treatment escalation should be driven by increasing recurrence risk 6. For lower-risk tumors like yours—particularly postmenopausal women with stage 1, ER-positive breast cancer with limited risk features—5 years of endocrine therapy alone is appropriate 6.

The 2024 NCCN guidelines support this approach, noting that for very low-risk disease, the absolute benefit from chemotherapy is minimal to nonexistent 7.

Treatment Algorithm for This Patient

Recommended Approach:

1. Primary treatment: Endocrine therapy for 5-10 years

   • Postmenopausal: Aromatase inhibitor (preferred) or tamoxifen 1
   • Premenopausal: Tamoxifen ± ovarian function suppression (only if higher-risk features present, which your patient lacks) 1

2. No chemotherapy indicated given:

   • Grade 1 histology
   • Ki-67 1% (extremely low)
   • Strong hormone receptor positivity expected
   • Node-negative status (assumed from question context)

3. Consider genomic testing ONLY if:

   • Tumor size >1 cm AND
   • Patient/physician uncertainty remains despite favorable pathology
   • However, with grade 1 and Ki-67 1%, genomic assays would almost certainly confirm low risk

Key Caveats:

• If lymph nodes are positive (≥4 nodes): Reconsider, though even then, grade 1 with Ki-67 1% suggests minimal chemotherapy benefit 1
• If tumor size is very large (T3-T4): May warrant multidisciplinary discussion, but biology still predicts poor chemotherapy response
• Premenopausal patients: May derive some benefit from chemotherapy-induced amenorrhea, but this is an endocrine effect, not cytotoxic benefit—ovarian function suppression is more appropriate 1

Why Chemotherapy Would Be Inappropriate Here

The 2009 ESMO guidelines noted that features indicating uncertain endocrine responsiveness include low hormone receptor levels, grade 3, high Ki-67, and HER2 overexpression 8. Your patient has none of these unfavorable features—she has the opposite profile entirely.

Research demonstrates that in tumors with no unfavorable factors (which would include your patient), only 3.6% developed metastasis without chemotherapy 9. The absolute risk reduction from chemotherapy in such cases would be negligible, far below the 3-5% threshold the 2025 St. Gallen panel identified as necessary to justify chemotherapy 6.

Bottom line: Chemotherapy would expose this patient to significant toxicity (neuropathy, cardiac risk, fatigue, alopecia) with essentially zero benefit. The tumor biology predicts excellent outcomes with endocrine therapy alone.